Comparative Pharmacology
Head-to-head clinical analysis: CALDEROL versus PARICALCITOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALDEROL versus PARICALCITOL.
CALDEROL vs PARICALCITOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vitamin D analog; binds to vitamin D receptors, increasing calcium absorption in intestines and promoting bone mineralization.
Paricalcitol is a synthetic vitamin D analog that binds to the vitamin D receptor (VDR) in target tissues, including the parathyroid glands, kidneys, and intestines. It selectively activates VDR to suppress parathyroid hormone (PTH) secretion, reduce parathyroid cell proliferation, and modulate calcium and phosphate homeostasis with lower calcemic and phosphatemic effects compared to calcitriol.
Oral: 0.25-0.5 mcg once daily; titration up to 1 mcg daily based on serum calcium levels. Intravenous: 0.5-2 mcg bolus; maintenance 0.5-2 mcg daily.
0.04 to 0.1 mcg/kg intravenously bolus no more frequently than every other day during dialysis, or 1 to 4 mcg orally once daily.
None Documented
None Documented
Clinical Note
moderateParicalcitol + Digoxin
"The risk or severity of adverse effects can be increased when Paricalcitol is combined with Digoxin."
Clinical Note
moderateParicalcitol + Hydrochlorothiazide
"Paricalcitol may increase the hypercalcemic activities of Hydrochlorothiazide."
Clinical Note
moderateParicalcitol + Bendroflumethiazide
"Paricalcitol may increase the hypercalcemic activities of Bendroflumethiazide."
Clinical Note
moderateParicalcitol + Methyclothiazide
Terminal elimination half-life is approximately 20-30 hours; clinically, steady-state is achieved within 5-7 days.
Terminal elimination half-life is approximately 5-7 hours in healthy subjects, but may be prolonged to 14-20 hours in patients with renal impairment.
Primarily fecal (biliary) as unchanged drug and metabolites (approx. 80%); renal excretion accounts for less than 20%.
Primarily fecal (74%) via hepatobiliary excretion; renal elimination accounts for approximately 16% as unchanged drug.
Category C
Category C
Vitamin D Analog
Vitamin D Analog
"Paricalcitol may increase the hypercalcemic activities of Methyclothiazide."